Affiliation:
1. Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA
2. Cleveland Clinic Foundation Cleveland Ohio USA
3. Gilbert and Rose‐Marie Chagoury School of Medicine Lebanese American University Byblos Lebanon
Abstract
Background
Residual risk of cardiovascular events and plaque progression remains despite reduction in low‐density lipoprotein cholesterol. Factors contributing to residual risk remain unclear. The authors examined the role of eicosapentaenoic acid and docosahexaenoic acid in coronary plaque regression and its predictors.
Methods and Results
A total of 240 patients with stable coronary artery disease were randomized to eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) or none for 30 months. Patients were stratified by regression or progression of coronary fatty plaque measured by coronary computed tomographic angiography. Cardiac events were ascertained. The mean±SD age was 63.0±7.7 years, mean low‐density lipoprotein cholesterol level was <2.07 mmol/L, and median triglyceride level was <1.38 mmol/L. Regressors had a 14.9% reduction in triglycerides that correlated with fatty plaque regression (
r
=0.135;
P
=0.036). Compared with regressors, progressors had higher cardiac events (5% vs 22.3%, respectively;
P
<0.001) and a 2.89‐fold increased risk of cardiac events (95% CI, 1.1–8.0;
P
=0.034). Baseline non–high‐density lipoprotein cholesterol level <2.59 mmol/L (100 mg/dL) and systolic blood pressure <125 mm Hg were significant independent predictors of fatty plaque regression. Normotensive patients taking eicosapentaenoic acid plus docosahexaenoic acid had regression of noncalcified coronary plaque that correlated with triglyceride reduction (
r
=0.35;
P
=0.034) and a significant decrease in neutrophil/lymphocyte ratio. In contrast, hypertensive patients had no change in noncalcified coronary plaque or neutrophil/lymphocyte ratio.
Conclusions
Triglyceride reduction, systolic blood pressure <125 mm Hg, and non–high‐density lipoprotein cholesterol <2.59 mmol/L were associated with coronary plaque regression and reduced cardiac events. Normotensive patients had greater benefit than hypertensive patients potentially due to lower levels of inflammation. Future studies should examine the role of inflammation in plaque regression.
Registration
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT01624727.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献